You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

Table 1.  

Association LOD Score Gene
1q22-24 3.45 FCGR 2A/3A
1q31 3.79  
1q41-42 3.3 SLEB1 locus
2q35-37 4.24 PDCD1, SLEB2 locus
4p16-15 3.84  
6p22-21 4.19 HLA-DR, DQ, C4, TNF
12q24 3.72  
16q12-13 3.85  

Susceptibility Loci for SLE

SLE = systemic lupus erythematosus; FCGR 2A/3A = Fc gamma receptor 2A/3A; HLA = human histocompatibility antigen; C = complement; PDCD = program cell death; TNF = tumor necrosis factor

Table 2.  

Chromosome Population Effect
6p21, MHC region United States; n, 266 pts LOD score > 3
6q27 United States; n, 266 pts LOD score > 3
19q13 United States; n, 266 pts LOD score > 3
12q23-24 United States; n, 266 pts Association
16p13 United States; n, 266 pts Association
7q21 United States; n, 266 pts Association
13q33-34 United States; n, 266 pts Association
Osteopontin polymorphisms United States; n, 821 No genetic association
Osteopontin wild-type 1284A allele United States; n, 821 Trend of increased risk for secondary progressive disease
2p, 3q, 5q, Xp United States; 98 families; France; 90 families Previously reported linkage not confirmed
1p34 United States; 98 families; France; 90 families LOD score > .9
3p14 United States; 98 families; France; 90 families LOD score > .9
19q13 United States; 98 families; France; 90 families LOD score > .9
17q11, NOS2A locus, D346D 2 African American data sets Association
17q22-24, PRKCA polymorphism United Kingdom; n, 184 Association
6p Canada; n, 552 affected sibling pairs LOD, 4.4
2q27 Canada; n, 552 affected sibling pairs LOD, 2.27
5p15 Canada; n, 552 affected sibling pairs LOD, 2.09
18p11 Canada; n, 552 affected sibling pairs LOD, 1.68
9q21 Canada; n, 552 affected sibling pairs LOD, 1.58
1p31 Canada; n, 552 affected sibling pairs LOD, 1.33
17q Canada; n, 552 affected sibling pairs LOD, 1.67
DRB1*15 Continental Italy; n, 609 Association; odds ratio, 3.64
DRB1*07 Continental Italy; n, 609 Negative association; odds ratio, .60
6p21.3 (the HLA region), 6q14.1 and 7q34 Portugal; n, 200 Association
6p21 Germany; n, 234 and Finland; n, 195 Association
7p15 France and United Kingdom; 104 families Association in HLA-DR15-negative patients
5p15 Turkey; n, 197 Association

Susceptibility Loci for Multiple Sclerosis

HLA = human histocompatibility antigen

CME

Genes and Autoimmune Diseases -- A Complex Inheritance

  • Authors: Sara M Mariani, MD, PhD
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
Start Activity


Target Audience and Goal Statement

This activity is intended for primary care physicians, rheumatologists, and other physicians who care for patients with autoimmune diseases.

The goal of this activity is to review current evidence describing the role of genetics in autoimmune diseases.

Upon completion of this activity, participants will be able to:

  1. Comment on the general relationship between genetics and autoimmune diseases.
  2. Identify mediators of rheumatoid arthritis.
  3. Describe the association of the PTPN22 allele with rheumatoid arthritis.
  4. Identify genetic and other factors involved in the development of systemic lupus erythematosus.
  5. Specify factors of inheritance of multiple sclerosis.


Disclosures

As an organization accredited by the ACCME, Medscape requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as "financial relationships in any amount, occurring within the past 12 months, that create a conflict of interest."

Medscape encourages Authors to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration, at first mention and where appropriate in the content.


Author(s)

  • Sara M Mariani, MD, PhD

    Deputy Editor, Medscape General Medicine; Site Editor/Program Director, Medscape Molecular Medicine

    Disclosures

    Disclosure: Sara M. Mariani, MD, PhD, has no significant financial interests or relationships to disclose.

CME Author(s)

  • Charles P Vega, MD

    Associate Professor; Residency Director, Department of Family Medicine, University of California, Irvine

    Disclosures

    Disclosure: Charles Vega, MD, FAAFP, has disclosed that he has received grants for educational activities from Pfizer.


Accreditation Statements

    For Physicians

  • Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Medscape designates this educational activity for a maximum of 0.5 category 1 credit(s) toward the AMA Physician's Recognition Award. Each physician should claim only those credits that reflect the time he/she actually spent in the activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page.

Follow these steps to earn CME/CE credit:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. Medscape encourages you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 5 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

The credit that you receive is based on your user profile.

CME

Genes and Autoimmune Diseases -- A Complex Inheritance

Authors: Sara M Mariani, MD, PhDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

processing....

The Genetics of Autoimmune Diseases

The fly sat upon the axle-tree of the chariot-wheel and said, "What a dust do I raise!"
Francis Bacon

About 3% to 5% of the US population is affected by an autoimmune disease, such as rheumatoid arthritis (RA), multiple sclerosis (MS), or systemic lupus erythematosus (SLE). Although it is still unclear what these diseases may have in common, they are generally grouped in the autoimmune category, as a dysregulation of the endogenous immune response (leading to damage of the patient's own tissues and organs) is thought to underlie their development and progression. RA and SLE predominantly affect the joints and the kidneys, whereas MS stems from demyelination in the central and peripheral nervous systems.

Far more women are affected than men, and heterogeneity in incidence is known to occur among different populations and different countries. MS, for example, manifests itself more frequently in young women of Northern rather than of Southern European descent. It is unclear whether such heterogeneity reflects genetic and/or environmental factors.

Cause and effect is still an elusive link in autoimmune diseases, and the therapies currently used reflect this lack of clear etiopathogenetic knowledge. All have a hereditary component, most probably polygenic in nature. Genetic regions and polymorphisms associated with each disease are being uncovered, and the most relevant were discussed at the 54th Annual Meeting of the American Society of Human Genetics, recently held in Toronto, Ontario, Canada.

Some gene associations have been confirmed, while others have been proven inconsistent or restricted to a specific population. More data will come in the near future, and they are expected to help in dissecting the genetic origin of autoimmune diseases and in unraveling their causes. In the meantime, we may want to remember that, sometimes, linkages and gene associations may just be flies sitting on a chariot wheel.